Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma (https://www.myeloma.org/videos/cevostamab-shows-promise-hard-treat-multiple-myeloma)
Abstract title:
Cevostamab in Patients with RRMM Who Are Triple-Class Refractory and Have Received a Prior BCMA-Targeted ADC or CAR T-Cell: Initial Results from the Phase I/II CAMMA 2 Study
Summary:
Cevostamab, a FcRH5xCD3 bispecific antibody, has shown promising activity in patients with heavily pre-treated relapsed/refractory multiple myeloma (RRMM), including those with prior exposure to BCMA-targeted agents. The Phase I/II CAMMA 2 study is evaluating the efficacy and safety of cevostamab in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted antibody–drug conjugate (ADC) or chimeric antigen receptor (CAR) T-cell therapy. In Cohort A1 of the study, 21 patients (median age: 64 years) were enrolled, with 10 patients having received a prior ADC and 11 patients having received a prior CAR T-cell therapy. The median prior lines of therapy for these patients was 6. Among all patients, an overall response rate (ORR) of 67% was achieved, with 38% achieving a very good partial response (VGPR) or better. The ORR and VGPR or better rates were higher in the prior CAR T-cell group compared to the prior ADC group. Grade 3-4 adverse events occurred in 62% of patients, with neutropenia, anemia, and thrombocytopenia being the most common. Infections occurred in 38% of patients, with 10% being grade 3-4. Serious adverse events occurred in 48% of patients, with neutropenia being the most common. Cytokine release syndrome (CRS) occurred in 71% of patients, all of which were grade 1-2. The percentage of MMPCs expressing BCMA was higher in the prior ADC group compared to the prior CAR T-cell group. Overall, the initial data from Cohort A1 of CAMMA 2 demonstrate that cevostamab has promising activity and manageable safety in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell therapy.
Key Points:
- Cevostamab, a FcRH5xCD3 bispecific antibody, has shown promising activity in heavily pre-treated RRMM patients.
- The CAMMA 2 study is evaluating the efficacy and safety of cevostamab in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell therapy.
- In Cohort A1 of the study, 21 patients were enrolled, with 10 patients having received a prior ADC and 11 patients having received a prior CAR T-cell therapy.
- The overall response rate (ORR) was 67%, with 38% achieving a very good partial response (VGPR) or better.
- The ORR and VGPR or better rates were higher in the prior CAR T-cell group compared to the prior ADC group.
- Grade 3-4 adverse events occurred in 62% of patients, with neutropenia, anemia, and thrombocytopenia being the most common.
- Infections occurred in 38% of patients, with 10% being grade 3-4.
- Serious adverse events occurred in 48% of patients, with neutropenia being the most common.
- Cytokine release syndrome (CRS) occurred in 71% of patients, all of which were grade 1-2.
- The percentage of MMPCs expressing BCMA was higher in the prior ADC group compared to the prior CAR T-cell group.
- The initial data from Cohort A1 of CAMMA 2 demonstrate that cevostamab has promising activity and manageable safety in RRMM patients who are triple-class refractory and have received a prior BCMA-targeted ADC or CAR T-cell therapy.
Authors:
Shaji Kumar, Jesus Berdeja, Douglas Sborov, Paolo Corradini, Yael Cohen, Alexander Lesokhin, Moshe Gatt, Laura Paris, Laura Rosiñol, Hang Quach, Joshua Richter, Ameet Mishra, Oliver Catalani, Katerina Chineneyze, Paresh Sewpaul, Elisabeth Wassner Fritsch, Michel Delforge